Case report: Possible role of low-dose PEM for avoiding unneeded procedures associated with false-positive or equivocal breast MRI results

被引:2
|
作者
Rapley, Madeline [1 ]
Freitas, Vivianne [2 ]
Weinberg, Irving N. [3 ]
Baldassi, Brandon [4 ]
Poladyan, Harutyun [1 ]
Waterston, Michael [4 ]
Ghai, Sandeep [2 ]
Taeb, Samira [5 ]
Bubon, Oleksandr [1 ,4 ]
Reznik, Alla [1 ,6 ]
Mulligan, Anna Marie [7 ]
机构
[1] Lakehead Univ, Dept Phys, Thunder Bay, ON, Canada
[2] Univ Toronto, Temerty Fac Med, Joint Dept Med Imaging, Toronto, ON, Canada
[3] Weinberg Med Phys, Rockville, MD USA
[4] Radialis Inc, Thunder Bay, ON, Canada
[5] Univ Hlth Network, Princess Margaret Canc Ctr, Dept Res, Toronto, ON, Canada
[6] Thunder Bay Reg Hlth Sci Ctr, Thunder Bay, ON, Canada
[7] Univ Toronto, Univ Hlth Network, Toronto Gen Hosp Site, Lab Med Program, Toronto, ON, Canada
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
加拿大自然科学与工程研究理事会;
关键词
low-dose positron emission mammography; organ-targeted positron emission tomography; breast MRI; high specificity breast imaging; breast cancer overdiagnosis with MRI; POSITRON EMISSION MAMMOGRAPHY; RISK; WOMEN; MANAGEMENT;
D O I
10.3389/fonc.2024.1405404
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Contrast-enhanced breast magnetic resonance imaging (MRI) is currently recommended as a screening tool for high-risk women and has been advocated for women with radiologically dense breast tissue. While breast MRI is acknowledged for its high sensitivity (with an exception for lower-grade ductal carcinoma in situ (DCIS) where emerging techniques like diffusion-weighted imaging offer improvement), its limitations include sensitivity to hormonal changes and a relatively high false-positive rate, potentially leading to overdiagnosis, increased imaging uncertainty, and unnecessary biopsies. These factors can exacerbate patient anxiety and impose additional costs. Molecular imaging with breast-targeted Positron Emission Tomography (PET) has shown the capability to detect malignancy independent of breast density and hormonal changes. Furthermore, breast-targeted PET has shown higher specificity when compared with MRI. However, traditional PET technology is associated with high radiation dose, which can limit its widespread use particularly in repeated studies or for undiagnosed patients. In this case report, we present a clinical application of low-dose breast imaging utilizing a breast-targeted PET camera (Radialis PET imager, Radialis Inc). The case involves a 33-year-old female patient who had multiple enhanced lesions detected on breast MRI after surgical removal of a malignant phyllodes tumor from the right breast. A benign core biopsy was obtained from the largest lesion seen in the left breast. One month after the MRI, 18F-fluorodeoxyglucose (18F-FDG) PET imaging session was performed using the Radialis PET Imager. Although the Radialis PET Imager has proven high count sensitivity and the capability to detect breast lesions with low metabolic activity (at a dose similar to mammography), no areas of increased 18F-FDG uptake were visualized in this particular case. The patient underwent a right-sided nipple-sparing mastectomy and left-sided lumpectomy, with bilateral reconstruction. The excised left breast tissue was completely benign, as suggested by both core biopsy and the PET results. The case presented highlights a promising clinical application of low-dose breast-targeted PET imaging to mitigate the uncertainty associated with MRI while keeping radiation doses within the safe range typically used in X-ray mammography.
引用
收藏
页数:6
相关论文
共 10 条
  • [1] Possible role of low-dose PEM for avoiding unneeded procedures associated with false-positive or equivocal breast MRI results ( vol 14 , 1405404 , 2024)
    Rapley, Madeline
    Freitas, Vivianne
    Weinberg, Irving N.
    Baldassi, Brandon
    Poladyan, Harutyun
    Waterston, Michael
    Ghai, Sandeep
    Taeb, Samira
    Bubon, Oleksandr
    Mulligan, Anna Marie
    Reznik, Alla
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [2] Kaiser score diagnosis of breast MRI lesions: Factors associated with false-negative and false-positive results
    Zhang, Bing
    Guo, Zhuanzhuan
    Lei, Zhe
    Liang, Wenbin
    Chen, Xin
    EUROPEAN JOURNAL OF RADIOLOGY, 2024, 178
  • [3] Yield of Serum Dexamethasone Measurement for Reducing False-Positive Results of Low-Dose Dexamethasone Suppression Testing
    Roper, Stephen M.
    JOURNAL OF APPLIED LABORATORY MEDICINE, 2021, 6 (02): : 480 - 485
  • [4] False-Positive Buprenorphine EIA Urine Toxicology Results Due To High Dose Morphine: A Case Report
    Tenore, Peter L.
    JOURNAL OF ADDICTIVE DISEASES, 2012, 31 (04) : 329 - 331
  • [5] Low-dose computed tomography was associated with higher risk for false-positive lung cancer screening than chest radiography
    Stanbrook, Matthew B.
    ANNALS OF INTERNAL MEDICINE, 2010, 153 (04)
  • [6] Myelin Oligodendrocyte Glycoprotein Antibody- Associated Disease With False-Positive Results in SARS-CoV-2 Antigen Tests: A Case Report
    Yamamoto, Naoki
    Ikenouchi, Hajime
    Takai, Yoshiki
    Endo, Kaoru
    Aoki, Masashi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (11)
  • [7] Low-dose apatinib in combination with chemotherapy for hormone receptor-positive, HER2-negative breast cancer with pulmonary lymphangitic carcinomatosis: A case report
    Chen, Liping
    Feng, Sha
    Chen, Xuelian
    Du, Caiwen
    MEDICINE, 2024, 103 (45)
  • [8] Analytical interference in CA 19-9 immunoassay generates false-positive results in a young woman with a low-grade appendiceal tumor: an educational case report and brief literature review
    Denis, Jerome A.
    Boissan, Mathieu
    Rouzaud, Eric
    Lacorte, Jean-Marc
    Pocard, Marc
    Genser, Laurent
    ANNALES DE BIOLOGIE CLINIQUE, 2024, 82 (03) : 321 - 328
  • [9] Role of PSA Density and MRI in PSA Interpretation. Comment on Lumbreras et al. Variables Associated with False-Positive PSA Results: A Cohort Study with Real-World Data. Cancers 2023, 15, 261
    Jue, Joshua S.
    Alameddine, Mahmoud
    CANCERS, 2023, 15 (09)
  • [10] Reply to Jue, JS']JS; Alameddine, M. Role of PSA Density and MRI in PSA Interpretation. Comment on "Lumbreras et al. Variables Associated with False-Positive PSA Results: A Cohort Study with Real-World Data. Cancers 2023, 15, 261"
    Lumbreras, Blanca
    Parker, Lucy Anne
    Caballero-Romeu, Juan Pablo
    Gomez-Perez, Luis
    Puig-Garcia, Marta
    Lopez-Garrigos, Maite
    Garcia, Nuria
    Hernandez-Aguado, Ildefonso
    CANCERS, 2023, 15 (10)